It Seems Denali Therapeutics Inc. (DNLI) Will Go Up. Have Another Big Increase

February 15, 2018 - By Winifred Garcia

The stock of Denali Therapeutics Inc. (NASDAQ:DNLI) is a huge mover today! The stock increased 10.49% or $2.19 during the last trading session, reaching $23.12. About 110,886 shares traded. Denali Therapeutics Inc. (NASDAQ:DNLI) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.
The move comes after 7 months positive chart setup for the $2.08 billion company. It was reported on Feb, 15 by We have $24.51 PT which if reached, will make NASDAQ:DNLI worth $124.98M more.

More notable recent Denali Therapeutics Inc. (NASDAQ:DNLI) news were published by: which released: “The Funded: Denali Therapeutics sets IPO price range; 4 others raise rounds” on November 29, 2017, also with their article: “3 Key Questions For Denali Therapeutics Investors” published on January 02, 2018, published: “Drug maker led by Genenexers, and targeting Alzheimer’s, Parkinson’s and ALS …” on November 14, 2017. More interesting news about Denali Therapeutics Inc. (NASDAQ:DNLI) were released by: and their article: “Denali Therapeutics Files To Raise $100 Million IPO” published on November 17, 2017 as well as‘s news article titled: “Why this $300 million biotech IPO could be huge — or another flop in …” with publication date: December 07, 2017.

Denali Therapeutics Inc., a biopharmaceutical company, engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company has market cap of $2.08 billion. The company's lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson's disease. It currently has negative earnings. It is also developing therapeutics for the treatment of Parkinson's, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.